The short-term efficacy and safety of induction chemotherapy combined with PD-1 inhibitor or anti-EGFR in locoregionally advanced nasopharyngeal carcinoma

被引:3
|
作者
Xiang, Xiaoyong [1 ,2 ]
Chen, Peng [1 ,2 ]
Lan, Fengming [1 ,2 ]
Ma, Li [1 ,2 ]
Jin, Jing [1 ,2 ,3 ]
Zhang, Ye [3 ]
机构
[1] Chinese Acad Med Sci & Peking Union Med Coll, Canc Hosp & Shenzhen Hosp, Natl Canc Ctr, Natl Clin Res Ctr Canc, Shenzhen, Peoples R China
[2] Chinese Acad Med Sci & Peking Union Med Coll, Shenzhen Hosp, Shenzhen, Peoples R China
[3] Chinese Acad Med Sci & Peking Union Med Coll, Canc Hosp, Natl Canc Ctr, Natl Clin Res Ctr Canc,Dept Radiat Oncol, Beijing, Peoples R China
来源
FRONTIERS IN ONCOLOGY | 2023年 / 13卷
关键词
nasopharyngeal carcinoma; locoregionally advanced; induction chemotherapy; short-term efficacy; PD-1; GROWTH-FACTOR RECEPTOR; CHEMORADIOTHERAPY; MULTICENTER; RADIOTHERAPY; GEMCITABINE; EXPRESSION; PLACEBO; PHASE-3; NPC;
D O I
10.3389/fonc.2023.1110281
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
PurposeThis study aimed to investigate the short-term efficacy and safety of induction chemotherapy (IC) combined with PD-1 inhibitor or anti-EGFR in the treatment of locoregionally advanced nasopharyngeal carcinoma (LA-NPC). Methods and materialsWe retrospectively reviewed the clinical data of 206 patients with LA-NPC, including IC combined with anti-PD-1 (57 patients), IC combined with anti-EGFR (28 patients), and IC alone (121 patients). The short-term efficacy was assessed at the end of IC and one month after overall treatment. According to the RECIST v1.1, the short-term efficacy of cervical lymph nodes and primary nasopharynx foci was divided into complete remission (CR), partial remission (PR), stable disease (SD), and progressive disease (PD). The overall response (ORR) was defined as the sum of CR and PR. Acute toxicities were graded according to the CTCAE v5.0. One-way analysis of variance (ANOVA) was used to compare differences in the numerical variables among groups. Fisher Freeman-Halton test or Pearson Chi-square test was used to compare classified variables. ResultsThe ORR rates of primary nasopharynx foci in IC, anti-EGFR, and anti-PD-1 group were 68.60%, 67.9%, and 94.7%, respectively, and the corresponding rates of ORR in cervical lymph nodes were 78.5%, 71.4%, and 93.0%, respectively. There was a statistical difference in the ORR between the three groups. Further analysis showed that after IC or overall treatment, the CR rate of primary nasopharynx foci in the anti-PD-1 group was significantly higher than the other two groups. The most common adverse effects were hematotoxicity, gastrointestinal toxicity, and transaminase elevation. However, there were no statistical differences in the frequency of any common adverse effects between the three groups. ConclusionsThe addition of anti-PD-1 based on IC significantly improved the short-term efficacy of LA-NPC and toxicities were tolerable.
引用
收藏
页数:10
相关论文
共 50 条
  • [31] The efficacy of anti-PD-1 immune checkpoint inhibitor in nasopharyngeal carcinoma
    Park, Jong Chul
    Durbeck, Julia
    Boudadi, Karim
    Ho, Wen Jin
    Kang, Hyunseok
    ORAL ONCOLOGY, 2020, 108
  • [32] Treatment outcomes of induction chemotherapy combined with intensity-modulated radiotherapy and adjuvant chemotherapy for locoregionally advanced nasopharyngeal carcinoma in Southeast China
    Wang, Peirong
    Dong, Feng
    Cai, Chuanshu
    Ke, Chunlin
    MEDICINE, 2021, 100 (33)
  • [33] Efficacy of adjuvant chemotherapy/maintenance chemotherapy after induction chemotherapy and concurrent chemoradiotherapy in patients with locoregionally advanced nasopharyngeal carcinoma: Experiences of two centers
    Tao, Hao-Yun
    He, Fang
    Shi, Qi-Yun
    Liu, Ran
    Wang, Zhi-Long
    Du, Kun-Peng
    Li, Jian-Feng
    Liu, Hui
    Lu, Zhi-Qiang
    Zhang, Jing-Jing
    Bai, Yu-Hai
    CANCER MEDICINE, 2023, 12 (06): : 6811 - 6824
  • [34] Short-term efficacy and safety of treatment of advanced hepatocellular carcinoma with sorafenib
    Castroagudin, J. F.
    Molina, E.
    Otero, E.
    Tome, S.
    Lopez, R.
    Varo, E.
    JOURNAL OF HEPATOLOGY, 2008, 48 : S141 - S142
  • [35] Efficacy and safety of CTLA-4 inhibitors combined with PD-1 inhibitors or chemotherapy in patients with advanced melanoma
    Zhang, Bo
    Zhou, You Lang
    Chen, Xinming
    Wang, Ziheng
    Wang, Qiuhong
    Ju, Fei
    Ren, Shiqi
    Xu, Ran
    Xue, Qun
    Wu, Qiong
    INTERNATIONAL IMMUNOPHARMACOLOGY, 2019, 68 : 131 - 136
  • [36] The efficacy and safety of docetaxel, cisplatin and fluorouracil (TPF)-based induction chemotherapy followed by concurrent chemoradiotherapy for locoregionally advanced nasopharyngeal carcinoma: a meta-analysis
    Zhou, R.
    Zhu, J.
    Chen, X.
    Liu, Y.
    Wang, Y.
    Zhang, T.
    CLINICAL & TRANSLATIONAL ONCOLOGY, 2020, 22 (03): : 429 - 439
  • [37] The efficacy and safety of docetaxel, cisplatin and fluorouracil (TPF)-based induction chemotherapy followed by concurrent chemoradiotherapy for locoregionally advanced nasopharyngeal carcinoma: a meta-analysis
    R. Zhou
    J. Zhu
    X. Chen
    Y. Liu
    Y. Wang
    T. Zhang
    Clinical and Translational Oncology, 2020, 22 : 429 - 439
  • [38] Efficacy and Safety of Re-Challenging PD-1 Inhibitors in Second-Line Treatment in Metastatic Nasopharyngeal Carcinoma Previously Treated with Chemotherapy and PD-1 Inhibitors
    Bei, Weixin
    Dong, Shuhui
    Liu, Guoying
    Lin, Lanfeng
    Jiang, Yaofei
    Lu, Nian
    Li, Wangzhong
    Liang, Hu
    Xiang, Yanqun
    Xia, Weixiong
    CANCER MANAGEMENT AND RESEARCH, 2024, 16 : 771 - 780
  • [39] Deep learning models for predicting short-term efficacy in locally advanced nasopharyngeal carcinoma
    Shi, K.
    Zhou, S.
    Yuan, J.
    Luo, J.
    Qiu, L.
    Xu, W.
    Fei, Y.
    Zhu, Y.
    ANNALS OF ONCOLOGY, 2024, 35 : S649 - S649
  • [40] Efficacy and safety of PD-1 inhibitor combined with antiangiogenic therapy for unresectable hepatocellular carcinoma: A multicenter retrospective study
    Yao, Junlin
    Zhu, Xudong
    Wu, Zhiheng
    Wei, Qing
    Cai, Yibo
    Zheng, Yu
    Hu, Xinyu
    Hu, Hong
    Zhang, Xiangyu
    Pan, Hongming
    Zhong, Xian
    Han, Weidong
    CANCER MEDICINE, 2022, 11 (19): : 3612 - 3622